NCT02166047 is a Phase 2 clinical trial of Vesatolimod in Chronic Hepatitis B, sponsored by Gilead Sciences.

Who is sponsoring NCT02166047?

NCT02166047 is sponsored by Gilead Sciences.

What drugs are being tested in NCT02166047?

Interventions in NCT02166047: Vesatolimod, Placebo.

What condition does NCT02166047 study?

NCT02166047 studies Chronic Hepatitis B.

Is NCT02166047 still recruiting?

NCT02166047 is currently completed. Last updated 14 October 2020.

Are results published for NCT02166047?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-10-14 · How we verify

NCT02166047

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

Completed Phase 2 Results posted Last updated 14 October 2020

What this trial tests

Phase 2 trial testing Vesatolimod in Chronic Hepatitis B in 162 participants. Completed in 20 October 2016.

Timeline

30 June 2014

Primary endpoint
11 May 2016

20 October 2016

Quick facts

Lead sponsor	Gilead Sciences
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	162
Start date	30 June 2014
Primary completion	11 May 2016
Estimated completion	20 October 2016
Sites	23 locations across Italy, New Zealand, Netherlands, South Korea, Canada, United States

Drugs / interventions tested

Vesatolimod — full drug profile →
Placebo

Conditions studied

Chronic Hepatitis B — all drugs for Chronic Hepatitis B →

Sponsor

Gilead Sciences — full company profile →

Who can join

Adults 18 to 65, any sex, with Chronic Hepatitis B. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Level at Week 24 Primary · Baseline to Week 24

A mixed effect model for repeated measures (MMRM) was used to analyze HBsAg change from baseline, which included treatment, baseline HBsAg level (\> 5000 IU/mL or ≤ 5000 IU/mL), HBeAg baseline status (positive or negative), visit and treatment-by-visit interaction as fixed effect and visit as repeated measurement.

Group	Value	95% CI
Vesatolimod 1 mg 4 Weeks (Cohort A)	-0.011	-0.054 – 0.031
Vesatolimod 2 mg 4 Weeks (Cohort A)	0.033	-0.012 – 0.079
Vesatolimod 4 mg 4 Weeks (Cohort A)	-0.018	-0.062 – 0.026
Placebo 4 Weeks (Cohort A)	-0.035	-0.109 – 0.040
Vesatolimod 1 mg 8 Weeks (Cohort B)	-0.081	-0.145 – -0.016
Vesatolimod 2 mg 8 Weeks (Cohort B)	-0.081	-0.147 – -0.014
Vesatolimod 4 mg 8 Weeks (Cohort B)	-0.082	-0.148 – -0.015
Placebo 8 Weeks (Cohort B)	-0.163	-0.281 – -0.045
Vesatolimod 1 mg 12 Weeks (Cohort C)	-0.015	-0.057 – 0.027
Vesatolimod 2 mg 12 Weeks (Cohort C)	0.000	-0.041 – 0.042
Vesatolimod 4 mg 12 Weeks (Cohort C)	0.000	-0.046 – 0.047
Placebo 12 Weeks (Cohort C)	0.001	-0.057 – 0.058

Composite Endpoint Measuring the Percentage of Participants With Hepatitis B Envelope Antigen (HBeAg) Loss and Seroconversion at Week 24 Secondary · Week 24

HBeAg loss was defined as qualitative HBeAg result changing from positive at baseline to negative at any postbaseline visit within the targeted time window. HBeAg seroconversion was defined as qualitative hepatitis B envelope antibody (HBeAb) result changing from negative at baseline to positive at any postbaseline visit within the targeted time window. Participants who had missing information were assumed to have no HBeAg loss and no HBeAg seroconversion.

Group	Value	95% CI
Vesatolimod 1 mg 4 Weeks (Cohort A)	0.0
Vesatolimod 2 mg 4 Weeks (Cohort A)	0.0
Vesatolimod 4 mg 4 Weeks (Cohort A)	0.0
Placebo 4 Weeks (Cohort A)	0.0
Vesatolimod 1 mg 8 Weeks (Cohort B)	20.0
Vesatolimod 2 mg 8 Weeks (Cohort B)	0.0
Vesatolimod 4 mg 8 Weeks (Cohort B)	0.0
Vesatolimod 1 mg 12 Weeks (Cohort C)	0.0
Vesatolimod 2 mg 12 Weeks (Cohort C)	0.0
Vesatolimod 4 mg 12 Weeks (Cohort C)	0.0
Placebo 12 Weeks (Cohort C)	0.0

Composite Endpoint Measuring the Percentage of Participants With Hepatitis B Envelope Antigen (HBeAg) Loss and Seroconversion at Week 48 Secondary · Week 48

Group	Value	95% CI
Vesatolimod 1 mg 4 Weeks (Cohort A)	0.0
Vesatolimod 2 mg 4 Weeks (Cohort A)	0.0
Vesatolimod 4 mg 4 Weeks (Cohort A)	0.0
Placebo 4 Weeks (Cohort A)	0.0
Vesatolimod 1 mg 8 Weeks (Cohort B)	20.0
Vesatolimod 2 mg 8 Weeks (Cohort B)	0.0
Vesatolimod 4 mg 8 Weeks (Cohort B)	0.0
Vesatolimod 1 mg 12 Weeks (Cohort C)	33.3
Vesatolimod 2 mg 12 Weeks (Cohort C)	0.0
Vesatolimod 4 mg 12 Weeks (Cohort C)	0.0
Placebo 12 Weeks (Cohort C)	0.0

Composite Endpoint Measuring the Percentage of Participants With HBsAg Loss and Seroconversion at Week 24 Secondary · Week 24

HBsAg loss was defined as qualitative HBsAg result changing from positive at baseline to negative at any postbaseline visit within the targeted time window. HBsAg seroconversion was defined as qualitative hepatitis B surface antibody (HBsAb) result changing from negative at baseline to positive at any postbaseline visit within the targeted time window. Participants who had missing information were assumed to have no HBsAg loss and no HBsAg seroconversion.

Group	Value	95% CI
Vesatolimod 1 mg 4 Weeks (Cohort A)	0
Vesatolimod 2 mg 4 Weeks (Cohort A)	0
Vesatolimod 4 mg 4 Weeks (Cohort A)	0
Placebo 4 Weeks (Cohort A)	0
Vesatolimod 1 mg 8 Weeks (Cohort B)	0
Vesatolimod 2 mg 8 Weeks (Cohort B)	0
Vesatolimod 4 mg 8 Weeks (Cohort B)	0
Placebo 8 Weeks (Cohort B)	0
Vesatolimod 1 mg 12 Weeks (Cohort C)	0
Vesatolimod 2 mg 12 Weeks (Cohort C)	0
Vesatolimod 4 mg 12 Weeks (Cohort C)	0
Placebo 12 Weeks (Cohort C)	0

Composite Endpoint Measuring the Percentage of Participants With HBsAg Loss and Seroconversion at Week 48 Secondary · Week 48

Group	Value	95% CI
Vesatolimod 1 mg 4 Weeks (Cohort A)	0.0
Vesatolimod 2 mg 4 Weeks (Cohort A)	0.0
Vesatolimod 4 mg 4 Weeks (Cohort A)	0.0
Placebo 4 Weeks (Cohort A)	0.0
Vesatolimod 1 mg 8 Weeks (Cohort B)	0.0
Vesatolimod 2 mg 8 Weeks (Cohort B)	0.0
Vesatolimod 4 mg 8 Weeks (Cohort B)	0.0
Placebo 8 Weeks (Cohort B)	0.0
Vesatolimod 1 mg 12 Weeks (Cohort C)	0.0
Vesatolimod 2 mg 12 Weeks (Cohort C)	0.0
Vesatolimod 4 mg 12 Weeks (Cohort C)	0.0
Placebo 12 Weeks (Cohort C)	0.0

Change From Baseline in Serum HBsAg Level at Week 4 Secondary · Baseline; Week 4

Group	Value	95% CI
Vesatolimod 1 mg 4 Weeks (Cohort A)	-0.009	± 0.0505
Vesatolimod 2 mg 4 Weeks (Cohort A)	0.025	± 0.0514
Vesatolimod 4 mg 4 Weeks (Cohort A)	-0.008	± 0.0516
Placebo 4 Weeks (Cohort A)	-0.017	± 0.0600
Vesatolimod 1 mg 8 Weeks (Cohort B)	-0.003	± 0.0574
Vesatolimod 2 mg 8 Weeks (Cohort B)	0.014	± 0.0794
Vesatolimod 4 mg 8 Weeks (Cohort B)	-0.001	± 0.0436
Placebo 8 Weeks (Cohort B)	0.046	± 0.0648
Vesatolimod 1 mg 12 Weeks (Cohort C)	-0.034	± 0.0375
Vesatolimod 2 mg 12 Weeks (Cohort C)	-0.023	± 0.0529
Vesatolimod 4 mg 12 Weeks (Cohort C)	-0.001	± 0.0627
Placebo 12 Weeks (Cohort C)	-0.041	± 0.0955

Change From Baseline in Serum HBsAg Level at Week 8 Secondary · Baseline; Week 8

Group	Value	95% CI
Vesatolimod 1 mg 4 Weeks (Cohort A)	-0.029	± 0.0666
Vesatolimod 2 mg 4 Weeks (Cohort A)	0.002	± 0.0544
Vesatolimod 4 mg 4 Weeks (Cohort A)	-0.035	± 0.0649
Placebo 4 Weeks (Cohort A)	-0.013	± 0.0440
Vesatolimod 1 mg 8 Weeks (Cohort B)	0.000	± 0.0442
Vesatolimod 2 mg 8 Weeks (Cohort B)	0.006	± 0.0772
Vesatolimod 4 mg 8 Weeks (Cohort B)	0.020	± 0.0596
Placebo 8 Weeks (Cohort B)	0.006	± 0.0600
Vesatolimod 1 mg 12 Weeks (Cohort C)	-0.021	± 0.0376
Vesatolimod 2 mg 12 Weeks (Cohort C)	-0.033	± 0.0487
Vesatolimod 4 mg 12 Weeks (Cohort C)	-0.013	± 0.0426
Placebo 12 Weeks (Cohort C)	-0.019	± 0.0483

Change From Baseline in Serum HBsAg Level at Week 12 Secondary · Baseline; Week 12

Group	Value	95% CI
Vesatolimod 1 mg 4 Weeks (Cohort A)	-0.050	± 0.0755
Vesatolimod 2 mg 4 Weeks (Cohort A)	0.017	± 0.0646
Vesatolimod 4 mg 4 Weeks (Cohort A)	-0.004	± 0.0546
Placebo 4 Weeks (Cohort A)	-0.023	± 0.0623
Vesatolimod 1 mg 8 Weeks (Cohort B)	-0.031	± 0.0817
Vesatolimod 2 mg 8 Weeks (Cohort B)	-0.005	± 0.0843
Vesatolimod 4 mg 8 Weeks (Cohort B)	-0.021	± 0.0716
Placebo 8 Weeks (Cohort B)	-0.020	± 0.0666
Vesatolimod 1 mg 12 Weeks (Cohort C)	-0.023	± 0.0545
Vesatolimod 2 mg 12 Weeks (Cohort C)	-0.034	± 0.0549
Vesatolimod 4 mg 12 Weeks (Cohort C)	-0.010	± 0.0621
Placebo 12 Weeks (Cohort C)	-0.024	± 0.0661

Change From Baseline in Serum HBsAg Level at Week 48 Secondary · Baseline; Week 48

Group	Value	95% CI
Vesatolimod 1 mg 4 Weeks (Cohort A)	-0.048	± 0.1054
Vesatolimod 2 mg 4 Weeks (Cohort A)	-0.055	± 0.1400
Vesatolimod 4 mg 4 Weeks (Cohort A)	-0.071	± 0.0857
Placebo 4 Weeks (Cohort A)	-0.067	± 0.0831
Vesatolimod 1 mg 8 Weeks (Cohort B)	-0.035	± 0.0923
Vesatolimod 2 mg 8 Weeks (Cohort B)	-0.024	± 0.0679
Vesatolimod 4 mg 8 Weeks (Cohort B)	-0.114	± 0.2169
Placebo 8 Weeks (Cohort B)	-0.324	± 0.6811
Vesatolimod 1 mg 12 Weeks (Cohort C)	-0.083	± 0.0858
Vesatolimod 2 mg 12 Weeks (Cohort C)	-0.071	± 0.1076
Vesatolimod 4 mg 12 Weeks (Cohort C)	-0.054	± 0.0715
Placebo 12 Weeks (Cohort C)	-0.063	± 0.1011

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse Events: First dose date up to Week 12 plus 30 days; All-Cause Mortality: Baseline up to Week 48. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Vesatolimod 1 mg 4 Weeks (Cohort A)

Serious: 0/16 (0%)

Deaths: 0/16

Vesatolimod 2 mg 4 Weeks (Cohort A)

Serious: 1/15 (7%)

Deaths: 0/15

Vesatolimod 4 mg 4 Weeks (Cohort A)

Serious: 1/16 (6%)

Deaths: 0/16

Placebo 4 Weeks (Cohort A)

Serious: 0/5 (0%)

Deaths: 0/5

Vesatolimod 1 mg 8 Weeks (Cohort B)

Serious: 0/18 (0%)

Deaths: 0/18

Vesatolimod 2 mg 8 Weeks (Cohort B)

Serious: 0/17 (0%)

Deaths: 0/17

Vesatolimod 4 mg 8 Weeks (Cohort B)

Serious: 0/17 (0%)

Deaths: 0/17

Placebo 8 Weeks (Cohort B)

Serious: 0/5 (0%)

Deaths: 0/5

Vesatolimod 1 mg 12 Weeks (Cohort C)

Serious: 0/16 (0%)

Deaths: 0/16

Vesatolimod 2 mg 12 Weeks (Cohort C)

Serious: 1/17 (6%)

Deaths: 0/17

Vesatolimod 4 mg 12 Weeks (Cohort C)

Serious: 1/14 (7%)

Deaths: 0/14

Placebo 12 Weeks (Cohort C)

Serious: 0/6 (0%)

Deaths: 0/6

Serious adverse events (8 terms)

Reaction	System	Vesatolimod 1 mg 4 Weeks (…	Vesatolimod 2 mg 4 Weeks (…	Vesatolimod 4 mg 4 Weeks (…	Placebo 4 Weeks (Cohort A)	Vesatolimod 1 mg 8 Weeks (…	Vesatolimod 2 mg 8 Weeks (…	Vesatolimod 4 mg 8 Weeks (…	Placebo 8 Weeks (Cohort B)	Vesatolimod 1 mg 12 Weeks …	Vesatolimod 2 mg 12 Weeks …	Vesatolimod 4 mg 12 Weeks …	Placebo 12 Weeks (Cohort C)
Cataract	Eye disorders	—	—	—	—	—	—	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Cholecystitis	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Tremor	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Hot flush	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—	—
Hypotension	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (120 terms — click to expand)

Reaction	System	Vesatolimod 1 mg 4 Weeks (…	Vesatolimod 2 mg 4 Weeks (…	Vesatolimod 4 mg 4 Weeks (…	Placebo 4 Weeks (Cohort A)	Vesatolimod 1 mg 8 Weeks (…	Vesatolimod 2 mg 8 Weeks (…	Vesatolimod 4 mg 8 Weeks (…	Placebo 8 Weeks (Cohort B)	Vesatolimod 1 mg 12 Weeks …	Vesatolimod 2 mg 12 Weeks …	Vesatolimod 4 mg 12 Weeks …	Placebo 12 Weeks (Cohort C)
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Influenza like illness	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Somnolence	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—	—	—	—	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Acne	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—
Ear swelling	Ear and labyrinth disorders	—	—	—	—	—	—	—	—	—	—	—	—
Vertigo positional	Ear and labyrinth disorders	—	—	—	—	—	—	—	—	—	—	—	—
Asthenopia	Eye disorders	—	—	—	—	—	—	—	—	—	—	—	—
Diplopia	Eye disorders	—	—	—	—	—	—	—	—	—	—	—	—
Dry eye	Eye disorders	—	—	—	—	—	—	—	—	—	—	—	—
Glaucoma	Eye disorders	—	—	—	—	—	—	—	—	—	—	—	—
Photophobia	Eye disorders	—	—	—	—	—	—	—	—	—	—	—	—
Photopsia	Eye disorders	—	—	—	—	—	—	—	—	—	—	—	—
Visual acuity reduced	Eye disorders	—	—	—	—	—	—	—	—	—	—	—	—
Vitreous floaters	Eye disorders	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal distension	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain lower	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Dental caries	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Epigastric discomfort	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Haemorrhoids	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Mouth cyst	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Mouth ulceration	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Paraesthesia oral	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Rectal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Toothache	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—	—	—	—	—	—	—
Feeling cold	General disorders	—	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Cataract, Chills, Pyrexia, Cholecystitis, Headache, Tremor, Hot flush, Hypotension.

Data from ClinicalTrials.gov NCT02166047 adverse events section.

Sponsor's own description

The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod in participants with chronic hepatitis B (CHB) infection currently being treated with oral antivirals (OAV). Participants will be randomized in 3 sequential cohorts (Cohorts A, B, and C). Within each cohort, participants will be randomized in a 1:3:3:3 ratio to placebo or one of the doses of vesatolimod (1, 2, or 4 mg).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Present and future therapies of hepatitis B: From discovery to cure.
Liang TJ, Block TM, McMahon BJ, Ghany MG, et al · · 2015 · cited 245× · PMID 26239691 · DOI 10.1002/hep.28025
Recent clinical trends in Toll-like receptor targeting therapeutics.
Anwar MA, Shah M, Kim J, Choi S. · · 2019 · cited 209× · PMID 30450666 · DOI 10.1002/med.21553
HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment.
Singh KP, Crane M, Audsley J, Avihingsanon A, et al · · 2017 · cited 190× · PMID 28692539 · DOI 10.1097/qad.0000000000001574
TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection.
Owen AM, Fults JB, Patil NK, Hernandez A, et al · · 2020 · cited 101× · PMID 33679711 · DOI 10.3389/fimmu.2020.622614
Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.
Patinote C, Karroum NB, Moarbess G, Cirnat N, et al · · 2020 · cited 87× · PMID 32203790 · DOI 10.1016/j.ejmech.2020.112238
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives.
Sun H, Li Y, Zhang P, Xing H, et al · · 2022 · cited 86× · PMID 36476317 · DOI 10.1186/s40364-022-00436-7
Hepatitis B Virus Cure: Targets and Future Therapies.
Lee HW, Lee JS, Ahn SH. · · 2020 · cited 75× · PMID 33379331 · DOI 10.3390/ijms22010213
Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies.
Farooq M, Batool M, Kim MS, Choi S. · · 2021 · cited 70× · PMID 34671606 · DOI 10.3389/fcell.2021.756315

Verify or expand the search:

Other trials of Vesatolimod

Trials testing the same drug.

NCT05458102 — Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels · Phase 1 · terminated
NCT05281510 — Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women · Phase 2 · completed
NCT03060447 — Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) · Phase 1 · completed
NCT02579382 — Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarat · Phase 2 · completed
NCT02858401 — Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults · Phase 1 · completed

Other recruiting trials for Chronic Hepatitis B

Currently open trials in the same condition.

NCT07275918 — SA1211 Injection Phase 1 Study · Phase 1 · recruiting
NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
NCT07135349 — A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B · Phase 2 · active not recruiting
NCT07307586 — A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatiti · Phase 3 · recruiting
NCT07246889 — Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) · Phase 3 · active not recruiting

Other Gilead Sciences trials

Trials by the same sponsor.

NCT07115368 — Study of GS-1219 in Participants With HIV-1 · Phase 1 · terminated
NCT06784973 — Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated
NCT06683482 — A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain · completed
NCT06613685 — Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated · Phase 2, PHASE3 · terminated
NCT06585150 — Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02166047 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gilead Sciences
Last refreshed: 14 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02166047.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02166047

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (8 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Vesatolimod

Other recruiting trials for Chronic Hepatitis B

Other Gilead Sciences trials

Verify against primary sources